Latest Veterans News

Rokeby Resources (ASX:RKB) has secured the Omeo Gold Project in Victoria, adding a historical resource of 320,000 ounces at 4.0 g/t Au and launching a $4 million capital raise. The acquisition ushers in leadership changes and sets a clear path for resource expansion.

American Rare Earths is fast-tracking its Wyoming Halleck Creek rare earths project, defining a pilot plant pathway, advancing oxide to metal studies, and targeting a NASDAQ listing by year-end 2026.

Alligator Energy has moved into uranium extraction at its Samphire project, reporting initial Field Recovery Trial results that meet or exceed expectations and launching a Bankable Feasibility Study to underpin development.

Kalamazoo Resources reported a robust cash balance of AUD 8.8 million at quarter end, underpinned by a significant equity raise that offsets ongoing exploration and administrative outflows. The company’s funding runway extends beyond three quarters, positioning it to advance its Ashburton Gold Project drilling activities.

Cooper Metals has acquired the Pyramid Gold Project in North Queensland through an asset swap with AIC Mines, exchanging its Oorindi Project and raising nearly $1 million to fund exploration. The deal adds a high-grade, underexplored gold asset to Cooper’s portfolio, with drilling set to ramp up across multiple projects.

Great Dirt Resources bolstered its leadership with key industry veterans, secured $1.446 million in funding, and reported promising lithium anomalies at its Pilbara Project, all while renewing its NSW manganese exploration licence.

DeSoto Resources has reported strong gold assay results from artisanal workings at its Timbakouna Project and extensive soil sampling across multiple permits in Guinea’s prolific Siguiri Basin, underpinning plans for follow-up drilling and geophysical surveys.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.

Orthocell has swiftly converted regulatory approval into clinical use with the first Remplir™ surgery completed in a US Department of Defense hospital, marking a key step in its US commercial expansion.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.